Investment Summary

Education Growth Partners and Eight Roads Invest In Fuse Universal

On June 18, 2015, private equity firms Education Growth Partners and Eight Roads invested in education company Fuse Universal

Investment Highlights
  • This is Education Growth Partners’ 3rd and Eight Roads’ 3rd transaction in the Education sector.
  • This is Education Growth Partners’ 1st and Eight Roads’ 6th transaction in the United Kingdom.

Investment Summary

Date 2015-06-18
Target Fuse Universal
Sector Education
Investor(s) Education Growth Partners
Eight Roads
Deal Type Venture

Target

Fuse Universal

Canterbury, United Kingdom
Fuse Universal is a technology company helping global, enterprise, education and public sector organizations revolutionize online learning, knowledge sharing, and communication in the workplace. Fuse Universal was founded in 2008 and is based in London, United Kingdom.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 2

DESCRIPTION

Education Growth Partners is a private equity firm focused on the education sector. Specific areas of interest include education institutions, educational services, tech-based solutions and services, and publishing/content providers. Transactions of interest include small buyouts and funding growth capital needs. Education Growth Partners is based in Stamford, Connecticut.


DEAL STATS #
Overall 6 of 10
Sector (Education) 3 of 5
Type (Venture) 1 of 2
Country (United Kingdom) 1 of 1
Year (2015) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-05-19 Human Capital Institute

Cincinnati, Ohio, United States

Human Capital Institute is a provider of events and educational resources focused on human capital management with an emphasis on information and training regarding the ability to recruit and retain profitable employees. Human Capital Institute was founded in 2005 and is based in Cincinnati, Ohio.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-23 Sightlines

Guilford, Connecticut, United States

Sightlines LLC is a provider of facilities benchmarking data and expertise to higher education institutions. Sightlines was founded in 2000 and is based in Guilford, Connecticut.

Sell -
Investor
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.


DEAL STATS #
Overall 107 of 298
Sector (Education) 3 of 8
Type (Venture) 89 of 269
Country (United Kingdom) 6 of 18
Year (2015) 19 of 26
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-03 Medwell Ventures

Bangalore, India

Medwell Ventures provides specialty home healthcare services in India. It focuses on various therapeutic areas. The company offers various wellness and care programs ranging from preventive screening to home healthcare and palliative care. It provides bedside nursing care at home, as well as 24×7 medical services, such as physician consultation, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, pharmacy support, and related medical services. Medwell Ventures was founded in 2014 and is based in Bangalore, India.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-08 Compass Therapeutics

Boston, Massachusetts, United States

Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain-based multispecific platforms to empirically identify multispecific and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. Compass Therapeutics company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137 and is currently being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. Compass Therapeutics was incorporated in 2014 and is based in Boston, Massachusetts.

Buy -